Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy

Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy

Abstract Chronic infection with Kaposi’s sarcoma-associated herpes virus (KSHV) in B lymphocytes causes primary effusion lymphoma (PEL), the most aggressive form of KSHV-related cancer, which is resistant to conventional chemotherapy. In this study, we report that the BCBL-1 KSHV+ PEL cell line does...

Full description

Bibliographic Details
Main Authors: Tetsunori Sakamoto, Masahiko Ajiro, Akira Watanabe, Shingo Matsushima, Keiji Ueda, Masatoshi Hagiwara
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Cancer
Subjects:
Kaposi’s sarcoma-associated herpesvirus
Primary effusion lymphoma
FIT-039
Cyclin-dependent kinase 9
BCBL-1 xenograft
Online Access:https://doi.org/10.1186/s12885-023-10540-y

Internet

https://doi.org/10.1186/s12885-023-10540-y

Similar Items